Available Trials

Genitourinary Cancer

For more information regarding these studies, contact Cancer Research & Registry at (601) 984-1095.

Neoadjuvant: High-risk Clinically-localized Prostate

RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

This study is being done to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles to hormone therapy and radiation therapy to the whole pelvic body area to find out which is better.

Principal Investigator: Srinivasan Vijayakumar, MD

S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

The purpose of this study is to find out what effects (good and/or bad) there are to replacing Casodex (bicalutamide) with the experimental drug TAK-700 (also called orteronel) in Androgen Deprivation Therapy (ADT). ADT is hormone therapy used to treat prostate cancer. The study will evaluate how hormone therapy and TAK-700 work in comparison to hormone therapy and bicalutamide. The combination of TAK-700 and hormone therapy is considered experimental, while the combination of bicalutamide and hormone therapy is considered standard care for prostate cancer.

Principal Investigator: Barbara Craft, MD

Advanced Kidney/Renal

S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

This randomized phase II study to find out how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate, crizotinib, volitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Principal Investigator: John C. Henegan, MD

Bladder

No trials for bladder cancer are being conducted at UMMC/UMHC.

Urinary Tract

EA8141: Chemotherapy prior to surgery for cancer of the upper urinary tract

This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin hydrochloride, cisplatin, gemcitabine hydrochloride, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Removing the affected upper urinary tract by surgery is the recommended treatment for upper urinary tract cancer, but can cause loss of kidney function and prevent patients from being able to receive chemotherapy after surgery. Giving chemotherapy before surgery, when the kidneys are working at their maximum, may allow less tissue to be removed during surgery and may be more effective in treating patients with high grade upper urinary tract cancer. This study is for aggressive cancer of the upper urinary tract.

Principal Investigator: Louis Punkey, MD